Last update 18 Nov 2026

Dostarlimab-gxly

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Dostarlimab, Dostarlimab subcutaneous injection(Tesaro), Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
+ [12]
Target
Action
inhibitors
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Priority Review (Australia), Commissioner's National Priority Voucher (United States)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
MSI-H/dMMR Rectal Cancer
United States
19 Oct 2026
Advanced Endometrial Carcinoma
European Union
12 Jan 2024
Advanced Endometrial Carcinoma
Iceland
12 Jan 2024
Advanced Endometrial Carcinoma
Liechtenstein
12 Jan 2024
Advanced Endometrial Carcinoma
Norway
12 Jan 2024
Recurrent Endometrial Cancer
European Union
12 Jan 2024
Recurrent Endometrial Cancer
Iceland
12 Jan 2024
Recurrent Endometrial Cancer
Liechtenstein
12 Jan 2024
Recurrent Endometrial Cancer
Norway
12 Jan 2024
MSI-H/dMMR Solid Tumors
United States
17 Aug 2021
Mismatch repair-deficient Endometrial Carcinoma
European Union
21 Apr 2021
Mismatch repair-deficient Endometrial Carcinoma
Iceland
21 Apr 2021
Mismatch repair-deficient Endometrial Carcinoma
Liechtenstein
21 Apr 2021
Mismatch repair-deficient Endometrial Carcinoma
Norway
21 Apr 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
PD-L1 positive Non-Small Cell Lung CancerPhase 3
United States
10 Jun 2024
PD-L1 positive Non-Small Cell Lung CancerPhase 3
China
10 Jun 2024
PD-L1 positive Non-Small Cell Lung CancerPhase 3
Japan
10 Jun 2024
PD-L1 positive Non-Small Cell Lung CancerPhase 3
Argentina
10 Jun 2024
PD-L1 positive Non-Small Cell Lung CancerPhase 3
Belgium
10 Jun 2024
PD-L1 positive Non-Small Cell Lung CancerPhase 3
Brazil
10 Jun 2024
PD-L1 positive Non-Small Cell Lung CancerPhase 3
Bulgaria
10 Jun 2024
PD-L1 positive Non-Small Cell Lung CancerPhase 3
Canada
10 Jun 2024
PD-L1 positive Non-Small Cell Lung CancerPhase 3
Finland
10 Jun 2024
PD-L1 positive Non-Small Cell Lung CancerPhase 3
France
10 Jun 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
117
vxetiemgot(ywjvnwxumu) = Most patients had either reversible grade 1 or 2 adverse events, 60%, or no adverse events, 35%. fnfeharkbi (nygkfnwxxm )
Positive
04 Nov 2026
Phase 3
Non-Small Cell Lung Cancer
Adjuvant
PD-1 | PD-L1
3,213
Neoadjuvant-only platinum chemotherapy + PD-1/PD-L1 inhibitor
igvdimmbpf(szfrnwiddt): HR = 0.59 (95.0% CI, 0.52 - 0.67)
Positive
04 Nov 2026
Perioperative platinum chemotherapy + PD-1/PD-L1 inhibitor
Not Applicable
1
tsadzgwfls(vucpaieqjn) = kerdfzxuxi ayqceovaww (knflsxalwx )
Positive
04 Nov 2026
Phase 2
289
Dostarlimab + chemotherapy
xprlgdfjwh(qhmyuqvevj) = qmxpymglqt onlantcoga (xufcbxaitc )
Positive
23 Oct 2026
Phase 2
73
fpwgzxhcod(bowchziksu) = hreiqejbrt oxvflukiwc (tjeerqnavh )
Positive
23 Oct 2026
Phase 2
59
zbjkwnovqk(cjhcbysfvy) = khtjkbkvag rhfevltrda (wmdclbxrtk )
Positive
23 Oct 2026
Not Applicable
203
suzomrngbh(cntzpuutrk) = wuzxbmqamv zgmrcamkam (ipfjmdelmw )
Positive
23 Oct 2026
Phase 3
Ovarian Cancer
First line
1,127
PBCT ± dost ± nira maintenance + bev
ikwsvjksyi(iabnmtimuw) = egqvegjeyw vycfolgcpb (culwkrnjaa )
Positive
23 Oct 2026
PBCT ± dost ± nira maintenance without bev
ikwsvjksyi(iabnmtimuw) = cpkeycbykr vycfolgcpb (culwkrnjaa )
Not Applicable
247
dostarlimab + chemotherapy
(MMRp/MSS)
eucevtiypm(bxdlfuplqs) = fprzfndkjc bezyskicjy (gnahgjqjmw )
Positive
23 Oct 2026
dostarlimab + chemotherapy
(dMMR/MSI-H)
eucevtiypm(bxdlfuplqs) = xwuzchhprs bezyskicjy (gnahgjqjmw )
Phase 2
58
(Dostarlimab (TSR-042) (Singly))
ygsbagympx = bzspjkhflo qqdmurozhb (hzruznhhap, nrjtpjborb - ybtfnfqysr)
-
20 Oct 2026
(Dostarlimab (TSR-042) and Cobolimab TSR-022 (Combination))
ygsbagympx = zismekhgyn qqdmurozhb (hzruznhhap, hsjffsjjve - buikzexihl)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free